Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Downgraded by Wolfe Research to Peer Perform

Wolfe Research lowered shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRYFree Report) from an outperform rating to a peer perform rating in a research note released on Tuesday, Briefing.com reports.

BAYRY has been the subject of several other reports. HSBC downgraded Bayer Aktiengesellschaft from a hold rating to a reduce rating in a report on Monday, December 18th. UBS Group downgraded Bayer Aktiengesellschaft from a buy rating to a neutral rating in a report on Monday, December 4th. Deutsche Bank Aktiengesellschaft cut Bayer Aktiengesellschaft from a buy rating to a hold rating in a research report on Tuesday, November 14th. Finally, Jefferies Financial Group cut Bayer Aktiengesellschaft from a buy rating to a hold rating in a research report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of Hold.

Check Out Our Latest Stock Report on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Price Performance

Bayer Aktiengesellschaft stock opened at $8.16 on Tuesday. Bayer Aktiengesellschaft has a fifty-two week low of $8.12 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.13 and a quick ratio of 0.71. The stock has a 50-day simple moving average of $8.91 and a 200-day simple moving average of $11.32.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) last posted its earnings results on Wednesday, November 8th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 15.24%. The firm had revenue of $11.26 billion during the quarter, compared to analysts’ expectations of $12.62 billion. As a group, research analysts forecast that Bayer Aktiengesellschaft will post 1.63 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.

Further Reading

Analyst Recommendations for Bayer Aktiengesellschaft (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.